Positron Emission Tomography Clinical Trials
240 recruitingProcedure
Phase 2125Phase 178Phase 332Early Phase 110Not Applicable9Phase 43
Showing 1–20 of 240 trials
Recruiting
Phase 1
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Recurrent Plasmablastic LymphomaRefractory Plasmablastic Lymphoma
National Cancer Institute (NCI)30 enrolled1 locationNCT07332507
Recruiting
Phase 2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Stage IV Nasopharyngeal Carcinoma AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8Stage II Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI)50 enrolled85 locationsNCT06064097
Recruiting
Phase 3
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled270 locationsNCT06337318
Recruiting
Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled322 locationsNCT06096844
Recruiting
Phase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled296 locationsNCT07061977
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled192 locationsNCT06589804
Recruiting
Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled55 locationsNCT04609046
Recruiting
Phase 2Phase 3
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)138 enrolled416 locationsNCT04402788
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled483 locationsNCT05564377
Recruiting
Phase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled88 locationsNCT06029270
Recruiting
Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled407 locationsNCT05675410
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled582 locationsNCT03866382
Recruiting
Phase 1Phase 2
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+2 more
National Cancer Institute (NCI)86 enrolled6 locationsNCT07147231
Recruiting
Phase 2
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Peritoneal Malignant Mesothelioma
National Cancer Institute (NCI)66 enrolled40 locationsNCT05001880
Recruiting
Phase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)1,978 enrolled72 locationsNCT07391774
Recruiting
Phase 1Phase 2
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Burkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDouble-Expressor Lymphoma
National Cancer Institute (NCI)50 enrolled8 locationsNCT07069699
Recruiting
Phase 2
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Washington69 enrolled1 locationNCT06039371
Recruiting
Phase 1Phase 2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
City of Hope Medical Center50 enrolled3 locationsNCT05861050
Recruiting
Phase 1
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
Breast CarcinomaColorectal Carcinoma
City of Hope Medical Center24 enrolled1 locationNCT06130826
Recruiting
Phase 1
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center28 enrolled1 locationNCT05098210